We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 09, 2019

Improved Survival With EGFR TKIs Plus Bevacizumab in Brain Metastases

European Journal of Cancer


Additional Info

European Journal of Cancer
EGFR-TKIs Plus Bevacizumab Demonstrated Survival Benefit Than EGFR-TKIs Alone in Patients With EGFR-Mutant NSCLC and Multiple Brain Metastases
Eur. J. Cancer 2019 Sep 27;121(xx)98-108, T Jiang, Y Zhang, X Li, C Zhao, X Chen, C Su, S Ren, N Yang, C Zhou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading